Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Autor: Newell, D R¹, Searle, K M², Westwood, N B², Burtles, S S², Cancer Research UK Phase I/II Clinical Trials Committee (CORPORATE AUTHOR)

Publikováno v: British Journal of Cancer. 8/4/2003, Vol. 89 Issue 3, p437-454. 18p.

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.

Autor: Newell, D R, Burtles, S S, Fox, B W, Jodrell, D I, Connors, T A

Publikováno v: British Journal of Cancer. 11/1/99, Vol. 81 Issue 5, p760. 9p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors

Autor: Gerrit Jansen, Schornagel, J. H., Westerhof, G. R., Rijksen, G., Newell, D. R., Jackman, A. L.

Publikováno v: Cancer Research, 50(23), 7544-8. American Association for Cancer Research Inc.
Scopus-Elsevier
Jansen, G, Schornagel, J H, Westerhof, G R, Rijksen, G, Newell, D R & Jackman, A L 1990, ' Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors ', Cancer Research, vol. 50, no. 23, pp. 7544-8 .

N10-Propargyl-5,8-dideazafolic acid (CB3717) and 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI-198,583) are potent folate-based inhibitors of thymidylate synthase. We studied the membrane transport and the growth-inhibitory effects of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::f542d3e3e1c8e9c14844f441c2520e06
https://research.vumc.nl/en/publications/52dc2d47-869f-4c01-9387-f9eed0cad281